Neoantigen-based melanoma-poly-ICLC vaccine

Drug Overview

Neoantigen-based melanoma-poly-ICLC vaccine(often referred to by the study name NeoVax) is an investigational, highly personalized cancer immunotherapy. It is custom-designed for each patient based on the unique genetic mutations (neoantigens) found only within their specific melanoma tumor cells. The vaccine consists of up to 20 synthetic long peptides combined with poly-ICLC (Hiltonol), a powerful immunostimulant that acts as a “viral mimic.”

In the clinical landscape of March 2026, this vaccine represents a major milestone in “bespoke” medicine. Unlike standard treatments, NeoVax is not an “off-the-shelf” product; it requires a complex manufacturing process involving tumor sequencing and algorithmic prediction. By injecting these patient-specific markers alongside poly-ICLC, the vaccine “trains” the immune system’s T-cells to recognize and eliminate any remaining melanoma cells that might cause a future recurrence.

• Generic Name: Neoantigen-based melanoma-poly-ICLC vaccine.
• Common Code Name: NeoVax.
• Drug Class: Personalized Cancer Vaccine; Peptide-based Immunotherapy.
• Mechanism: Active immunization using patient-specific neoantigen peptides to stimulate a cytotoxic T-lymphocyte (CTL) response, boosted by the TLR3 agonist poly-ICLC vaccine.
• Route of Administration: Subcutaneous (SC) or Intradermal (ID) injection.
• FDA Approval Status: Investigational. As of March 2026, this vaccine is not FDA-approved. It is currently being evaluated in Phase 1 and Phase 2 clinical trials, often in combination with checkpoint inhibitors like pembrolizumab or nivolumab.

What Is It and How Does It Work? (Mechanism of Action)

Neoantigen vaccines function as a “wanted poster” for the immune system, showing it exactly what the “criminal” cancer cells look like.

1. The Discovery Phase (The “Barcode”)

Every melanoma has its own set of mutations.

1. Biopsy & Sequencing: A sample of the tumor is removed, and its DNA/RNA is sequenced.
2. Comparison: Scientists compare the tumor’s genetic code to the patient’s healthy cells to identify mutations called neoantigens.
3. Selection: Sophisticated algorithms select up to 20 neoantigens that are most likely to trigger a strong immune response.

2. The Adjuvant: Poly-ICLC (The “Alarm”)

Peptides alone are often ignored by the body. Poly-ICLC is a synthetic double-stranded RNA that mimics a viral infection.

• TLR3 Activation: It binds to Toll-like receptor 3 (TLR3) on dendritic cells.
• Immune Alert: This tricks the body into thinking a virus is present, causing it to “wake up” and launch a massive attack against anything associated with the neoantigen peptides.

3. T-Cell Mobilization

The vaccine stimulates the production of CD4+ and CD8+ T-cells. These cells travel through the body and, upon finding a melanoma cell displaying those specific mutated markers, they initiate cell lysis (destruction).

Clinical Indications & Research Status (2026)

Research in early 2026 focuses on high-risk patients who have had their tumors surgically removed but are at a high risk of the cancer returning.

• Stage IIIB/C/D and Stage IV Melanoma: Primarily studied as an “adjuvant” therapy (after surgery) to prevent recurrence.
• Combination Therapies: The most promising results involve combining NeoVax with PD-1 inhibitors (like Nivolumab) or CTLA-4 inhibitors (like Ipilimumab). These drugs “unleash” the T-cells that the vaccine has “trained.”
• Durable Survival: Five-year data released in February 2026 for mRNA-based versions of this strategy (like Intismeran Autogene) showed a 49% reduction in the risk of recurrence or death, significantly bolstering confidence in the personalized vaccine approach.

Dosage and Administration Protocols

Because the vaccine must be custom-made, the timeline is longer than traditional treatments.

Safety Profile and Side Effects

The primary advantage of a neoantigen vaccine is its high specificity; it generally does not attack healthy cells.

Common Side Effects (>60%):

• Injection Site Reactions: Redness, swelling, pain, and “granulomas” (small lumps) where the shot was given.
• Constitutional Symptoms: Fever, chills, fatigue, and “flu-like” malaise that typically lasts 24–48 hours.
• Musculoskeletal: Myalgias (muscle pain) and arthralgias (joint pain).

Serious Risks:

• Immune-Related Adverse Events (irAEs): When combined with drugs like Nivolumab, there is a risk of inflammation in the lungs (pneumonitis), liver, or colon.
• Allergic Reactions: Rare risk of severe allergic response to the poly-ICLC or peptide components.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, researchers are using the NeoVax platform to study “Immune Memory Persistence.” In 2026, there is also intense focus on “Dendritic Cell Priming,” using agents like CDX-301 (Flt3L) to increase the number of dendritic cells available to “read” the vaccine’s peptides. Scientists are also exploring “Intra-nodal Delivery,” where the vaccine is injected directly into lymph nodes to maximize the T-cell response.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Surgical Sample: You must have a tumor biopsy of at least 1 cm (or 4 core biopsies) that is viable for sequencing.
• HLA Testing: Blood tests to ensure the algorithm can accurately predict which peptides will work with your specific immune system.

“Do’s and Don’ts” List:

• DO expect a “waiting period” of several months while the vaccine is being built. Standard therapy is usually continued during this time.
• DO report any signs of a “systemic” immune response, such as persistent high fever or shortness of breath.
• DON’T receive any live-virus vaccines (like those for shingles or MMR) during the treatment period without consulting your oncologist.
• DON’T ignore local site reactions; keeping the area clean is essential to prevent secondary infection.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Neoantigen-based melanoma-poly-ICLC vaccine is an investigational agent and is not approved by the U.S. FDA. Access is limited exclusively to registered clinical trials. Always consult with a qualified oncologist regarding your specific diagnosis and eligibility for research participation.